VPT
April 19, 2021
Ventripoint Extends Patent Portfolio with Foundational U.S. Provisional Patent Filing of Heart Motion Tracking Technology
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) has filed a U.S. provisional patent application for its novel cardiac measurement approach.This new measurement technique provides cardiologists with additional and more precise information about the function of the heart through…...
April 15, 2021
Ventripoint Announces Sponsorship for the 2021 Canadian Society of Echocardiography Weekend Conference
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce its sponsorship of the 2021 Canadian Society of Echocardiography (CSE) Virtual Echo Weekend Conference to be held this weekend on April 17-18, 2021.The CSE strives to promote…...
April 13, 2021
Ventripoint Diagnostics Begins Publication of Case Studies Showing Meritorious Use of the VMS Heart Analysis System
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) has published its first case study of the meritorious use of the Ventripoint VMS whole-heart analysis system (https://www.ventripoint.com/whitepapers-case-studies) in routine clinical practice.Dr. Gregory Skinner at East Midlands Congenital Heart Centre, Leicester,…...
March 16, 2021
Ventripoint JV Begins Process to have Heart Analysis System Certified for use in COVID Patients in China
Toronto, Ontario – TheNewswire – March 16, 2021 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) announces that its partner, Yutian Medical Shanghai Inc. (“Yutian”), has reported Chinese guidelines for the diagnosis and treatment of COVID-19 patients now…...
March 9, 2021
Ventripoint Passes Regulatory Inspection of Manufacturing Facility and Audit of Quality Assurance System
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce the Company has completed another successful NRTL inspection of their manufacturing facility for the manufacture of the VMS+ 3.0....
March 3, 2021
Ventripoint Diagnostics Receives Additional Innovation Assistance Program Funding and Updates Warrant Exercises
Toronto, Ontario – TheNewswire – March 3 2021 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) announces that it is receiving an additional temporary wage grant of up to $43,353 as part of the National Research Council of…...
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce that its partner, Yutian Medical Shanghai Inc. (“Yutian”), has reported a successful engagement with key opinion leaders in the echocardiography sector in China. A training session in…...
February 23, 2021
Ventripoint Heart Analysis System to be used at the Stollery Children’s Hospital to Study Atrial Dysfunction in Children
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is announcing the commencement of a new clinical study to measure atrial volumes and ejection fractions in children with suspected valvular disease. The study is being conducted by cardiologists in the…...
February 16, 2021
Ventripoint Advances Sales, Marketing, and Distribution Partnership in the Largest Market in World for Heart Disease: China
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) is pleased to provide a corporate update on sales and marketing activities in China by our joint-venture partner Yutian Medical Shanghai Inc. (“Yutian”)....
February 9, 2021
Ventripoint Diagnostics Upgrades Investor Relations Webpage
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) has released the company’s new Investor Relations (IR) section on the company’s website....